Arrowhead Financial Statements From 2010 to 2025

ARWR Stock  USD 15.10  0.50  3.21%   
Arrowhead Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Arrowhead Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Arrowhead Pharmaceuticals financial statements helps investors assess Arrowhead Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Arrowhead Pharmaceuticals' valuation are summarized below:
Gross Profit
2.5 M
Market Capitalization
2.1 B
Enterprise Value Revenue
832.6119
Revenue
2.5 M
Earnings Share
(5.15)
There are over one hundred nineteen available fundamental signals for Arrowhead Pharmaceuticals, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to validate Arrowhead Pharmaceuticals' prevailing fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 03/19/2025, Market Cap is likely to grow to about 3.3 B. Also, Enterprise Value is likely to grow to about 3.3 B

Arrowhead Pharmaceuticals Total Revenue

3.88 Million

Check Arrowhead Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arrowhead Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 22.5 M, Interest Expense of 35.3 M or Selling General Administrative of 84.4 M, as well as many indicators such as Price To Sales Ratio of 309, Dividend Yield of 0.0 or PTB Ratio of 11.82. Arrowhead financial statements analysis is a perfect complement when working with Arrowhead Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Arrowhead Pharmaceuticals Correlation against competitors.
To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.

Arrowhead Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.4 B1.3 B473.7 M
Slightly volatile
Short and Long Term Debt Total616.5 M587.1 M124.6 M
Slightly volatile
Other Current Liabilities103.2 M98.3 M35.7 M
Slightly volatile
Total Current Liabilities124.6 M118.6 M57 M
Slightly volatile
Property Plant And Equipment Net520.8 M496 M134.4 M
Slightly volatile
Accounts Payable13.8 M13.1 M8.2 M
Slightly volatile
Cash124 M118.1 M93.1 M
Slightly volatile
Non Current Assets Total536.5 M511 M184.1 M
Slightly volatile
Non Currrent Assets Other5.4 M5.2 MM
Slightly volatile
Cash And Short Term Investments822.3 M783.1 M282.5 M
Slightly volatile
Common Stock Total Equity239.1 K227.7 K167.9 K
Slightly volatile
Common Stock Shares Outstanding144.6 M137.8 M79.7 M
Slightly volatile
Liabilities And Stockholders Equity1.4 B1.3 B473.7 M
Slightly volatile
Other Current Assets17.5 M16.7 M7.2 M
Slightly volatile
Other Stockholder Equity2.2 B2.1 B876.8 M
Slightly volatile
Total Liabilities1.1 B1.1 B303.2 M
Slightly volatile
Property Plant And Equipment Gross590.8 M562.7 M147 M
Slightly volatile
Total Current Assets839.8 M799.8 M289.6 M
Slightly volatile
Short Term Debt7.7 M7.3 M3.6 M
Slightly volatile
Common Stock237.1 K249.6 K6.8 M
Pretty Stable
Current Deferred Revenue946.1 K995.9 K18.4 M
Pretty Stable
Non Current Liabilities TotalB972.4 M246.3 M
Slightly volatile
Long Term Debt474.8 M452.2 M206 M
Slightly volatile
Preferred Stock Total Equity13.6814.42.2 M
Slightly volatile
Property Plant Equipment405.2 M385.9 M108.6 M
Slightly volatile
Other Assets229.4 K241.5 K10.6 M
Pretty Stable
Good Will9.2 M17.7 M13.5 M
Slightly volatile
Intangible Assets10.2 M9.8 M12.1 M
Pretty Stable
Other Liabilities67.6 M64.3 M35.1 M
Slightly volatile
Net Tangible Assets202.9 M300.2 M196.5 M
Slightly volatile
Long Term Debt Total1.7 M2.4 M1.8 M
Slightly volatile
Capital Surpluse1.5 B1.4 B768 M
Slightly volatile
Non Current Liabilities Other576.6 M549.2 M171.7 M
Slightly volatile
Long Term Investments353.5 M336.6 M129.9 M
Slightly volatile
Short and Long Term Debt229.6 K201.4 K209.9 K
Pretty Stable
Net Invested Capital698.7 M665.4 M257.6 M
Slightly volatile
Net Working Capital715.2 M681.1 M218.7 M
Slightly volatile
Capital Stock237.1 K249.6 K6.8 M
Pretty Stable

Arrowhead Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization22.5 M21.4 M7.7 M
Slightly volatile
Selling General Administrative84.4 M88.9 M51.5 M
Slightly volatile
Selling And Marketing Expenses1.8 M1.9 M1.5 M
Slightly volatile
Total Revenue3.9 M4.1 M58.7 M
Slightly volatile
Gross Profit3.9 M4.1 M58.7 M
Slightly volatile
Other Operating Expenses730.1 M695.3 M242.9 M
Slightly volatile
Cost Of Revenue21.6 M14.4 M30.2 M
Slightly volatile
Total Operating Expenses730.1 M695.3 M242.9 M
Slightly volatile
Research Development610.8 M581.8 M186.6 M
Slightly volatile
Non Recurring1.8 M1.8 M2.6 M
Pretty Stable
Interest Income27.4 M26.1 M8.5 M
Slightly volatile
Reconciled Depreciation22.5 M21.4 M8.8 M
Slightly volatile

Arrowhead Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow133.9 M127.5 M88.4 M
Slightly volatile
Depreciation22.5 M21.4 M7.7 M
Slightly volatile
End Period Cash Flow124 M118.1 M93.1 M
Slightly volatile
Stock Based Compensation81.2 M66.6 M37.5 M
Slightly volatile
Change To Netincome109.2 M104 M45.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio309588633
Pretty Stable
Days Sales Outstanding1.811.9427
Slightly volatile
Average Payables6.8 M6.5 M5.4 M
Slightly volatile
Stock Based Compensation To Revenue22.7623.9513.5814
Very volatile
Capex To Depreciation7.196.853.3913
Slightly volatile
EV To Sales726691576
Pretty Stable
Payables Turnover3.433.273.3726
Slightly volatile
Sales General And Administrative To Revenue30.3831.9845.0228
Slightly volatile
Average Inventory3.6 M3.4 M2.5 M
Slightly volatile
Research And Ddevelopement To Revenue13512864.4231
Very volatile
Capex To Revenue37.6535.869.9181
Slightly volatile
Cash Per Share5.375.122.6805
Slightly volatile
Days Payables Outstanding85.8990.41966
Slightly volatile
Intangibles To Total Assets0.00820.00860.0864
Slightly volatile
Current Ratio4.196.074.8099
Pretty Stable
Receivables Turnover163155109
Slightly volatile
Capex Per Share1.121.060.4002
Slightly volatile
Average Receivables5.2 MM3.1 M
Slightly volatile
Revenue Per Share0.03240.03411.5641
Slightly volatile
Interest Debt Per Share4.955.2127.8411
Slightly volatile
Debt To Assets0.490.520.7271
Slightly volatile
Graham Number5.225.866.3944
Slightly volatile
Days Of Payables Outstanding85.8990.41966
Slightly volatile
Ebt Per Ebit1.461.171.3299
Slightly volatile
Quick Ratio4.196.074.8046
Pretty Stable
Net Income Per E B T1.091.131.253
Slightly volatile
Cash Ratio1.091.142.4387
Slightly volatile
Days Of Sales Outstanding1.811.9427
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.91.181.1497
Slightly volatile
Fixed Asset Turnover0.0090.00951.1283
Very volatile
Debt Ratio0.490.520.7271
Slightly volatile
Price Sales Ratio309588633
Pretty Stable
Asset Turnover0.00340.00360.1688
Pretty Stable
Gross Profit Margin0.540.860.8975
Very volatile

Arrowhead Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.3 B3.1 B1.9 B
Slightly volatile
Enterprise Value3.3 B3.1 B1.9 B
Slightly volatile

Arrowhead Fundamental Market Drivers

Forward Price Earnings111.1111
Cash And Short Term Investments681 M

Arrowhead Upcoming Events

6th of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of December 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
30th of September 2023
Last Financial Announcement
View

About Arrowhead Pharmaceuticals Financial Statements

Arrowhead Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Arrowhead Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Arrowhead Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arrowhead Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue995.9 K946.1 K
Total Revenue4.1 M3.9 M
Cost Of Revenue14.4 M21.6 M
Stock Based Compensation To Revenue 23.95  22.76 
Sales General And Administrative To Revenue 31.98  30.38 
Research And Ddevelopement To Revenue 128.21  134.62 
Capex To Revenue 35.86  37.65 
Revenue Per Share 0.03  0.03 
Ebit Per Revenue(194.66)(184.93)

Pair Trading with Arrowhead Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Arrowhead Stock

  0.65A Agilent TechnologiesPairCorr
  0.67ME 23Andme HoldingPairCorr

Moving against Arrowhead Stock

  0.55DVAX Dynavax TechnologiesPairCorr
  0.45VALN Valneva SE ADRPairCorr
The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.
The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Arrowhead Stock Analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.